AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)

Gary J. MacFarlane (Corresponding Author), Ejaz Pathan, Stefan Siebert, Jonathan Packham, Karl Gaffney, Ernest H. Choy, Raj Sengupta, Fabiola Atzeni, Kathryn R. Martin, Gareth T. Jones, Linda Dean

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

Background
Around 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.

Methods
The British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012–2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.

Results
One thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (n = 347) and a smaller cluster (n = 32) with axial and peripheral disease, and in both groups more than half of members met criteria for fibromyalgia. The remaining two clusters (n = 437, n = 462) had overall less severe disease however the one which showed greater disease activity and poorer quality of life had a higher proportion meeting fibromyalgia criteria (16% v. 4%). Within those meeting fibromyalgia criteria there were three clusters. The two main groups were defined by level of symptom severity with a smaller third cluster noted to have high average swollen and tender joint counts and high levels of comorbidity.

Conclusions
The major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.
Original languageEnglish
Article number19
JournalBMC Rheumatology
Volume3
DOIs
Publication statusPublished - 20 May 2019

Fingerprint

Fibromyalgia
Biological Products
Population Groups
Research
Cluster Analysis
Comorbidity
Therapeutics
Joints
Quality of Life
Inflammation

Cite this

@article{c9ede4d31c6a45b59760eca4f89fe867,
title = "AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS)",
abstract = "BackgroundAround 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.MethodsThe British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012–2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.ResultsOne thousand three hundred thirty-eight participants were included of whom 23{\%} met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (n = 347) and a smaller cluster (n = 32) with axial and peripheral disease, and in both groups more than half of members met criteria for fibromyalgia. The remaining two clusters (n = 437, n = 462) had overall less severe disease however the one which showed greater disease activity and poorer quality of life had a higher proportion meeting fibromyalgia criteria (16{\%} v. 4{\%}). Within those meeting fibromyalgia criteria there were three clusters. The two main groups were defined by level of symptom severity with a smaller third cluster noted to have high average swollen and tender joint counts and high levels of comorbidity.ConclusionsThe major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.",
author = "MacFarlane, {Gary J.} and Ejaz Pathan and Stefan Siebert and Jonathan Packham and Karl Gaffney and Choy, {Ernest H.} and Raj Sengupta and Fabiola Atzeni and Martin, {Kathryn R.} and Jones, {Gareth T.} and Linda Dean",
note = "Parties can apply for access to data from the BSRBR-AS through the British Society for Rheumatology Registers Committee. Information is available from the corresponding author. The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts and can provide comments but have no input into determining the topics for analysis, publication and no input into the work involved in this analysis. This analysis is part of the Fibromyalgia Optimal Management for patients with axial Spondyloarthritis (FOMAxS) study funded by Versus Arthritis (formerly Arthritis Research UK) (Grant No: 21378).",
year = "2019",
month = "5",
day = "20",
doi = "10.1186/s41927-019-0066-7",
language = "English",
volume = "3",
journal = "BMC Rheumatology",
issn = "2520-1026",
publisher = "BioMed Central",

}

TY - JOUR

T1 - AxSpA patients who also meet criteria for fibromyalgia

T2 - identifying distinct patient clusters using data from a UK national register (BSRBR-AS)

AU - MacFarlane, Gary J.

AU - Pathan, Ejaz

AU - Siebert, Stefan

AU - Packham, Jonathan

AU - Gaffney, Karl

AU - Choy, Ernest H.

AU - Sengupta, Raj

AU - Atzeni, Fabiola

AU - Martin, Kathryn R.

AU - Jones, Gareth T.

AU - Dean, Linda

N1 - Parties can apply for access to data from the BSRBR-AS through the British Society for Rheumatology Registers Committee. Information is available from the corresponding author. The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts and can provide comments but have no input into determining the topics for analysis, publication and no input into the work involved in this analysis. This analysis is part of the Fibromyalgia Optimal Management for patients with axial Spondyloarthritis (FOMAxS) study funded by Versus Arthritis (formerly Arthritis Research UK) (Grant No: 21378).

PY - 2019/5/20

Y1 - 2019/5/20

N2 - BackgroundAround 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.MethodsThe British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012–2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.ResultsOne thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (n = 347) and a smaller cluster (n = 32) with axial and peripheral disease, and in both groups more than half of members met criteria for fibromyalgia. The remaining two clusters (n = 437, n = 462) had overall less severe disease however the one which showed greater disease activity and poorer quality of life had a higher proportion meeting fibromyalgia criteria (16% v. 4%). Within those meeting fibromyalgia criteria there were three clusters. The two main groups were defined by level of symptom severity with a smaller third cluster noted to have high average swollen and tender joint counts and high levels of comorbidity.ConclusionsThe major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.

AB - BackgroundAround 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria for fibromyalgia and such patients have considerable unmet need. Identifying effective therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease severity has not been established. The aim of the current analysis was to determine whether distinct clusters of axSpA patients exist and if so to determine a) whether they differ in terms of prevalence of fibromyalgia and b) the features of patients in clusters with high prevalence.MethodsThe British Society for Rheumatology Biologics Register (BSRBR-AS) recruited axSpA patients from 83 centres 2012–2017. Clinical data, and information from patients was collected (including research criteria for fibromyalgia). Cluster analysis was undertaken using split samples for development and validation both in the whole population and the sub-group which met fibromyalgia criteria.ResultsOne thousand three hundred thirty-eight participants were included of whom 23% met research criteria for fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one which was primarily axial (n = 347) and a smaller cluster (n = 32) with axial and peripheral disease, and in both groups more than half of members met criteria for fibromyalgia. The remaining two clusters (n = 437, n = 462) had overall less severe disease however the one which showed greater disease activity and poorer quality of life had a higher proportion meeting fibromyalgia criteria (16% v. 4%). Within those meeting fibromyalgia criteria there were three clusters. The two main groups were defined by level of symptom severity with a smaller third cluster noted to have high average swollen and tender joint counts and high levels of comorbidity.ConclusionsThe major feature defining clusters with a high proportion of persons meeting criteria for fibromyalgia is high axSpA disease activity although clusters with features of fibromyalgia in the absence of high disease activity also show moderately high prevalence. Management may be most successful with pharmacologic therapy to target inflammation but enhanced by the concurrent use of non-pharmacologic therapy in such patients.

UR - https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-019-0066-7

UR - http://www.mendeley.com/research/axspa-patients-also-meet-criteria-fibromyalgia-identifying-distinct-patient-clusters-using-data-uk-n

U2 - 10.1186/s41927-019-0066-7

DO - 10.1186/s41927-019-0066-7

M3 - Article

VL - 3

JO - BMC Rheumatology

JF - BMC Rheumatology

SN - 2520-1026

M1 - 19

ER -